Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

B. Cepacia Hits ICUs Again, Raises Manufacturing Controls Questions

Executive Summary

Another outbreak of B. cepacia at hospital intensive care units in multiple states implicates manufacturing and supply chain controls on aqueous non-sterile drug products, particularly for those marketed over the counter under OTC monographs.

Advertisement

Related Content

FDA Offers Sage Advice On Contract Manufacturers: Don't Mix Drugs And Car Wax
FDA Enforcement And Compliance In Brief
OTC Monograph User Fees: FDA-Industry Talks Move From Basics To Details
How FDA and Industry Aim to Find and Eliminate Drug Recalls' Root Causes
Drug Recall Totals for 2008 Highlight Global Outsourcing and Other Risks

Topics

Advertisement
UsernamePublicRestriction

Register

PS119068

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel